Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients

Ann Hematol. 2011 Sep;90(9):1115-6. doi: 10.1007/s00277-010-1136-5. Epub 2010 Dec 22.
No abstract available

Publication types

  • Evaluation Study
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Boronic Acids / administration & dosage*
  • Bortezomib
  • Chemotherapy, Adjuvant
  • Dexamethasone / administration & dosage*
  • Dexamethasone / therapeutic use
  • Doxorubicin / administration & dosage
  • Doxorubicin / analogs & derivatives*
  • Female
  • Humans
  • Lenalidomide
  • Male
  • Middle Aged
  • Mitoxantrone / therapeutic use
  • Multiple Myeloma / drug therapy*
  • Polyethylene Glycols / administration & dosage*
  • Pyrazines / administration & dosage*
  • Retrospective Studies
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives*
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Boronic Acids
  • Pyrazines
  • liposomal doxorubicin
  • Polyethylene Glycols
  • Thalidomide
  • Vincristine
  • Bortezomib
  • Dexamethasone
  • Doxorubicin
  • Mitoxantrone
  • Lenalidomide

Supplementary concepts

  • VMD protocol